Secondary outcomes included the pooled rate and OR of retained gastric contents (RGC)
Look at the alternative: the PlexusDx Weight Management Protocols provide month-to-month tirzepatide in injection and oral formats, or take the Precision Peptide Genetic Test to read your metabolic pathway first
Detoxification : It assists in the detoxification of harmful substances, helping the body eliminate toxins and pollutants
Summary measures and synthesis of results The principal summary outcome was the relative risk (RR) of several GI adverse events in people with overweight or obesity receiving treatment with GLP-1 RA, including nausea, vomiting, diarrhea, constipation, abdominal distension, upper abdominal pain, abdominal pain, abdominal discomfort, gastroesophageal reflux disease, (GERD), eructation, flatulence, decreased appetite, cholelithiasis, gallstone-related, cholecystitis, acute cholecystitis, acute pancreatitis, viral gastroenteritis, hard feces, and infrequent bowel movements